Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China

doi:10.3748/wjg.v25.i44.6551

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7720)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

501

WORD

285

HTML

3010

Figures (1-1)

318

Tables (1-4)

276

Sum=4390

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1036

Download

2294

Sum=3330

Nov 28, 2019 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Nov 28, 2019; 25(44): 6551-6560
Published online Nov 28, 2019. doi: 10.3748/wjg.v25.i44.6551

Open in New Tab Full Size Figure Download Figure

Figure 1 Treatment of chronic hepatitis C virus patients with direct-acting antiviral agents. RVR: Rapid virological response; ETR: End of treatment response; SVR12: Sustained virological response at post-treatment week 12; ITT: Intention-to-treat; mITT: Modified ITT; SOF: Sofosbuvir; LDV: Ledipasvir; RBV: Ribavirin; DCV: Daclatasvir; mITT: Modified intention-to-treat; LTFU: Lost to follow-up; HIV: Human immunodeficiency virus.

Citation: Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560
URL: https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i44.6551